CClinicalTrials.gg
SuspendedNCT05008315Updated Jul 6, 2026

Effects of Soft Tissue Mobilization on Postsurgical Adhesions, Pain, Lumbopelvic Muscle Functions, Spinal Mobility, and Posture in Postpartum Women With Caesarean Section

An interventional study of Myofascial abdominal diaphragm release and Direct focused scar release technique in Postsurgical Adhesion, sponsored by YI-JU TSAI. Suspended at 1 site in Taiwan. Open to female participants aged 20 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-06.

Sponsored by YI-JU TSAI · Not applicable, Interventional, and Treatment

Why this study was suspended
The clinical trial has been suspended due to a lack of funding
Phase
Not applicable
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
20 Years to 65 Years
Sex
Female
01

Study summary

Postpartum women with C-section receiving deep and superficial tissue mobilization would have better improvement on pain, lumbopelvic muscle functions, spinal mobility, and posture compare to the superficial tissue mobilization and control group

02

Conditions studied

  • Postsurgical Adhesion
03

In context

Lead sponsor

YI-JU TSAI is the lead sponsor of 4 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 65 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Eligibility criteria

vaginal delivery

Inclusion Criteria:

  • Natural birth without C-section scar
  • Postpartum more than 6 months
  • Without any pain in the lumbopelvic region

C-section

Inclusion Criteria:

  • Healed C-section scar > six months
  • Scar with or without pain

Both mode of delivery

Exclusion Criteria:

  • Active infection or infectious disease in the pelvis or abdomen
  • Pain medications on days of measurements
  • Skin irritation and inflammation at the site of the scar
  • Currently pregnant or actively trying to get pregnant
  • History of radiation to the area
  • Any fracture around spine and pelvis
  • Any previous gynecologic and obstetric surgery
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
120 participants (estimated)

Study arms

  • Experimental
    deep and superficial tissue mobilization group

    include deep and superficial tissue mobilization

    Other: Myofascial abdominal diaphragm release · Other: Direct focused scar release technique · Other: Direct manipulations to visceral structures · Other: pelvic anatomy education

  • Active comparator
    superficial tissue mobilization group

    superficial tissue mobilization

    Other: Myofascial abdominal diaphragm release · Other: Direct focused scar release technique

  • Placebo comparator
    control group

    Sham (very light hand touch on the same location as the other two groups but without any treatment intention)

    Other: pelvic anatomy education · Other: sham

  • Other
    vaginal delivery group

    education session

    Other: pelvic anatomy education

Interventions

  • OtherMyofascial abdominal diaphragm release

    Myofascial abdominal diaphragm release

  • OtherDirect focused scar release technique

    Direct focused scar release technique

  • OtherDirect manipulations to visceral structures

    Direct manipulations to visceral structures

  • Otherpelvic anatomy education

    pelvic anatomy education

  • Othersham

    sham

06

What researchers measure

Primary outcomes

  1. Scar Characteristic: Extensibility

    The extensibility of the scar will be measured using the modified adheremeter in each of 4 directions including superior, inferior, medial and lateral and then the area of mobility will be calculated.

    Time frame: 8 weeks

  2. Scar Characteristic: Viscoelasticity

    The biomechanical and viscoelastic properties of the scar tissue will be measured using a non-invasive myometer

    Time frame: 8 weeks

  3. Scar Characteristic: Irritability

    The irritability of the scar will be measured using the digital pressure algometer for two conditions: first, when the pressure turns from discomfort to pain and the participant asks to stop, and then when the maximal pressure or pain the participant can tolerate.

    Time frame: 8 weeks

  4. Muscle function measures of lumbopelvic muscles

    Ultrasonography image for muscle thickness of lumbopelvic muscles during rest and maximum contraction.

    Time frame: 8 weeks

  5. Muscle function measures of pelvic floor muscle control

    Ultrasonography image for muscle thickness of pelvic floor muscle control during rest, maximum contraction

    Time frame: 8 weeks

  6. Spinal Mobility

    Range of motion for cervical, thoracic, and lumbar spine in the sagittal, frontal, and transverse plane as well as pelvic tilt will be assessed using the wireless double inclinometers

    Time frame: 8 weeks

  7. Myofascial Flexibility

    Straight leg raise test and Thomas test will be used to examine the muscle flexibility of the major lower extremity muscles.

    Time frame: 8 weeks

  8. Spinal Alignment and Posture

    Radiographic measurement, posture will be assessed using the photographic measurement. Reflective markers will first be placed and attached on the canthus of the eye, tragus of the ear, the spinous processes of C2, C7, T1, T3, T11, T12, L1, L5, S1, S5, and bilateral anterior superior iliac spine and posterior superior iliac spine in standing. The participants will be instructed to maintain their gaze straight ahead at a target adjusted for body height. Two standing photographs will be taken, one in the usual standing posture and the other in the best standing posture. Following the other two photographs will be taken, one in maximal pelvic anterior tilt and the other in the maximal pelvic posterior tilt.

    Time frame: 8 weeks

  9. Pain intensity measure of Visual Analogue Scale

    Visual Analogue Scale is a self-reported instrument assessing average pain intensity in currently. Possible score range from 0 (no pain) to 10 (worst possible pain).

    Time frame: 8 weeks

  10. Pain intensity measure of pelvic girdle questionnaire

    pelvic girdle questionnaire is a self-reported instrument assessing pelvic girdle pain intensity in currently. Questionnaire consisting of 20 activity items and 5 symptom items on a 4-point response scale. Possible score range from 0 (no pain) to 100 (worst possible pain).

    Time frame: 8 weeks

  11. Pain intensity measure of Oswestry Low Back Pain Disability Questionnaire

    Oswestry Low Back Pain Disability Questionnaire is a self-reported instrument assessing patient's permanent functional disability in currently. For each section the total possible score is 5: if the first statement is marked the section score = 0; if the last statement is marked, it = 5. The higher the score, the greater the degree of disability.

    Time frame: 8 weeks

Secondary outcomes

  1. Self-perceived Change Health Status: Global Rating of Change Scale (GROC)

    The GROC is a single-item instrument that provides a means of measuring self-perceived change in health status. The GROC uses the 15-point Likert scale to rate the perceived "overall change" on a continuum, with -7 (labeled "worse") on the left and +7 (labeled "better") on the right, and 0 in the middle (labeled "no change"), compared with the baseline

    Time frame: 8 weeks

  2. Patient and Observer Scar Assessment Scale (POSAS)

    The POSAS includes 2 numerical numeric scales: The Patient Scar Assessment Scale and the Observer Scar Assessment Scale. It objectively assesses vascularity, pigmentation, thickness, relief, pliability, and surface area, and incorporates patient subjective symptoms of pain, itching, color, stiffness, thickness, and relief.

    Time frame: 8 weeks

07

Study locations

1 site
  • National Cheng Kung University
    Tainan, Tainan 701, Taiwan
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05008315
Lead sponsor
YI-JU TSAI
Responsible party
YI-JU TSAI (professor, National Cheng Kung University) — Sponsor-investigator
First posted
Aug 17, 2021
Start date
Apr 8, 2023
Primary completion
Nov 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Jul 6, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is suspended, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion